---

PSA Test Alternatives: Blood, Urine, Genetic and MRI Tests Explained

By Mr Neil Haldar, Consultant Urological Surgeon

Updated August 2026

Is there a better test than PSA?

There is not yet a single test that has replaced PSA as the usual first step in detecting prostate cancer.

However, PSA no longer needs to be interpreted on its own. A repeat PSA measurement, PSA density, the free-to-total PSA ratio, newer blood tests such as the Prostate Health Index and Stockholm3, urine biomarkers, genetic risk assessment and prostate MRI can all make the diagnostic pathway more accurate.

Most of these are not true replacements for PSA. They are additional or “reflex” tests used after PSA has raised concern, helping to answer a more important question:

How likely is this man to have a clinically significant prostate cancer that needs to be found?

The greatest improvement has not come from a new blood test at all. It has come from using MRI before biopsy, combining the scan with PSA density, and performing more selective, targeted biopsies when genuinely required. Current European guidance recommends MRI before biopsy in men with suspected organ-confined prostate cancer and supports the use of MRI, calibrated risk calculators or additional biomarkers when deciding who needs a biopsy.

PSA tests and alternatives at a glance

Test	What it assesses	Where it fits	Does it replace PSA?
Repeat PSA	Confirms whether an elevated result persists	First step after a moderately raised result	No
Free-to-total PSA	Different forms of PSA in the blood	Refines risk when PSA is moderately raised	No
PSA density	PSA adjusted for prostate size	Helps interpret MRI and decide on biopsy	No
Prostate Health Index	Total PSA, free PSA and p2PSA	Estimates the risk of significant cancer	No
4Kscore	Four kallikrein proteins plus clinical factors	Estimates the risk of higher-grade cancer	No
Stockholm3	Proteins, genetic variants and clinical data	Advanced risk assessment before MRI or biopsy	Potential future screening role
MPS2	Eighteen prostate cancer-associated urine genes	Helps determine whether biopsy is needed	No
Polygenic risk score	Inherited genetic susceptibility	Identifies men who may benefit from closer testing	No
Prostate MRI	Suspicious areas within the prostate	Guides the decision to biopsy and biopsy targeting	No
Micro-ultrasound	High-resolution real-time prostate imaging	Possible alternative method of guiding biopsy	Not yet routinely

What does the PSA blood test measure?

PSA stands for prostate-specific antigen. It is a protein made by cells within the prostate gland. Its normal physiological role is to help liquefy semen after ejaculation.

Small quantities of PSA enter the bloodstream, where they can be measured in nanograms per millilitre, usually written as ng/mL.

The most important point is that PSA is prostate-specific, not prostate cancer-specific.

A raised PSA tells us that something may be affecting the prostate. It does not tell us, by itself, that the cause is cancer.

What can cause a raised PSA apart from cancer?

Several benign conditions and temporary factors can increase PSA.

Benign prostate enlargement

Benign prostatic hyperplasia, or BPH, is the commonest explanation for a moderately raised PSA. Larger prostates contain more PSA-producing tissue.

A PSA of 6 ng/mL may be concerning in a man with a 30 mL prostate but entirely compatible with benign enlargement in a man whose prostate measures 100 mL. This is why you should not interpret PSA without considering prostate volume.

Prostatitis or urinary infection

Inflammation and infection can cause substantial PSA rises. PSA may remain elevated for some time after the infection has settled.

A man with a newly raised PSA should therefore usually have his symptoms reviewed and, where appropriate, a urine test performed before interpreting the result.

Urinary retention and instrumentation

Acute urinary retention, catheterisation and recent procedures involving the prostate or urinary tract may affect PSA.

Ejaculation

Ejaculation can cause a temporary PSA rise. Avoiding ejaculation for approximately 48 hours before a planned PSA test is sensible.

Vigorous exercise and cycling

Prolonged cycling or other activities that place sustained pressure on the perineum may modestly affect PSA in some men. I generally advise avoiding long or unusually vigorous rides for 48 hours before the blood test.

Recent prostate biopsy or surgery

PSA should not normally be measured immediately after a prostate biopsy or operation. A waiting period of at least six weeks is often appropriate, depending on the procedure and clinical circumstances.

Official UK patient information has historically advised avoiding ejaculation and vigorous exercise for 48 hours before testing and allowing at least six weeks after a prostate biopsy.

Can medication lower PSA?

Yes. Finasteride and dutasteride are 5-alpha-reductase inhibitors used to treat benign prostate enlargement. Finasteride may also be prescribed for hair loss.

These drugs commonly reduce PSA by approximately half after six to twelve months of treatment. A measured PSA therefore needs to be interpreted in the context of the medication, the duration of treatment and previous results.

“Doubling” the measured PSA can provide a rough clinical adjustment, but the individual pattern over time remains important.

Always tell the doctor interpreting your PSA if you are taking:

• finasteride;
• dutasteride;
• a combined prostate medication containing either drug; or
• treatment for hair loss that may contain finasteride.

How can I have a PSA test in the UK?

Most men are not automatically invited for routine prostate cancer screening.

A man who is concerned about his risk can discuss PSA testing with his GP. The decision should take account of age, ethnicity, family history, symptoms, health, life expectancy and personal preferences.

European guidance recommends offering an informed discussion about early PSA testing from:

• age 50 for men at average risk;
• age 45 for men of African ancestry;
• age 45 where there is an important family history; and
• age 40 for men who carry a pathogenic BRCA2 variant.

These are not rigid instructions that every man should be tested at exactly those ages. They are reasonable points at which to discuss individual risk.

A man with symptoms, an abnormal prostate examination or a particularly strong family history may need assessment regardless of age.

Who is at increased risk of prostate cancer?

The principal established risk factors include:

• increasing age;
• Black ethnicity;
• a father or brother diagnosed with prostate cancer, particularly at a younger age;
• several relatives affected by prostate, breast, ovarian or pancreatic cancer;
• a pathogenic BRCA2 variant;
• certain other inherited cancer-predisposition variants.

In England, the lifetime risk of prostate cancer is estimated to be approximately one in four for Black men compared with approximately one in eight for White men.

Risk is not determined by a single factor. A man with several affected relatives, for example, may warrant a different testing strategy from a man of the same age with no family history and a consistently low PSA.

What is a normal PSA level?

There is no single PSA value below which cancer is impossible or above which cancer is certain.

NICE uses the following age-related thresholds when considering urgent referral for people with possible symptoms of prostate cancer:

Age	PSA threshold for referral
Under 40	Use clinical judgement
40–49	More than 2.5 ng/mL
50–59	More than 3.5 ng/mL
60–69	More than 4.5 ng/mL
70–79	More than 6.5 ng/mL
Over 79	Use clinical judgement

These are referral thresholds for symptomatic patients. They are not universal definitions of a “normal” PSA and should not be applied without context.

The old statement that “anything below 4 is normal” is particularly unhelpful.

A PSA of 3.2 ng/mL in a healthy 48-year-old with a small prostate may warrant careful assessment. A stable PSA of 5.5 ng/mL in a 75-year-old with a very large benign prostate may be much less concerning.

The number needs to be interpreted alongside:

• age;
• prostate size;
• previous PSA readings;
• medication;
• infection or inflammation;
• ethnicity;
• family history;
• examination findings;
• MRI findings; and
• overall health.

What are the limitations of PSA?

PSA has three main limitations.

1. A raised PSA does not necessarily mean cancer

Most men with a moderately raised PSA will not ultimately be found to have clinically significant prostate cancer.

This can lead to anxiety, repeat blood tests, scans and sometimes biopsies in men who do not have a cancer requiring treatment.

2. A reassuring PSA does not completely exclude cancer

Some prostate cancers produce relatively little PSA. A result below an age-related referral threshold makes significant cancer less likely, but it does not make it impossible.

Persistent symptoms, an abnormal examination, a strong family history or a concerning PSA trend may justify further assessment despite a relatively low number.

3. PSA can detect cancers that would never cause harm

Prostate cancer is biologically varied. Some tumours grow rapidly and threaten life. Others grow so slowly that they would never cause symptoms during the man’s natural lifetime.

Detecting an indolent cancer can cause unnecessary anxiety and, if treatment is not selected carefully, expose a man to urinary and sexual side effects without improving his life expectancy.

This problem is called overdiagnosis. It is one of the central reasons why universal PSA screening has remained controversial.

Does PSA screening save lives?

Large screening trials suggest that repeated PSA-based screening can reduce prostate cancer mortality, but the benefit is accompanied by false-positive results, overdiagnosis and the risk of unnecessary treatment.

The UK National Screening Committee concluded in 2026 that the evidence still did not support inviting the entire male population for screening. It recommended a much narrower programme for a specific group of men with inherited BRCA2 risk.

It is also important to understand that historical screening studies largely evaluated older diagnostic pathways.

In the past, a raised PSA often led directly to a systematic transrectal biopsy. Today, a raised result is more commonly:

1. repeated under standardised conditions;
2. interpreted alongside prostate size and risk factors;
3. followed by prostate MRI;
4. assessed using PSA density; and
5. biopsied selectively when the combined findings justify it.

The harms and benefits of this modern pathway may therefore differ from those seen in trials that began many years ago.

Should a raised PSA be repeated?

Frequently, yes—but not in every clinical situation.

For an otherwise well man with a moderately raised PSA, no suspicious examination findings and no urgent symptoms, repeating the test can prevent unnecessary investigation prompted by a temporary fluctuation.

European guidance recommends repeating PSA after approximately four weeks in asymptomatic men with an initial PSA between 3 and 10 ng/mL and no suspicious palpation findings. In the evidence reviewed by the guideline, a meaningful proportion of repeat results fell below the original threshold.

The repeat test should ideally be performed:

• at the same laboratory;
• after excluding or treating urinary infection;
• without ejaculation for 48 hours;
• without unusually vigorous cycling or exercise for 48 hours; and
• after considering recent retention, catheterisation or prostate procedures.

A very high PSA, an abnormal prostate, systemic illness or other concerning findings may require more urgent investigation rather than simply waiting for another test.

How can the PSA result itself be made more accurate?

Before considering expensive new biomarkers, several practical refinements can add considerable value.

Free-to-total PSA ratio

PSA circulates in the blood in both bound and unbound—or “free”—forms.

Men with prostate cancer tend, on average, to have a lower proportion of free PSA than men whose PSA elevation is caused by benign enlargement.

The free-to-total PSA ratio can be useful when the total PSA lies in an intermediate or uncertain range. A lower ratio increases concern, while a higher ratio is more reassuring.

It should not be interpreted as a standalone diagnosis. It adds another piece of information to the overall risk assessment.

PSA density

PSA density is one of the most useful calculations in contemporary prostate cancer diagnosis.

It is calculated as:

PSA density = PSA ÷ prostate volume

For example:

• PSA 7 ng/mL with a 100 mL prostate gives a PSA density of 0.07;
• PSA 7 ng/mL with a 30 mL prostate gives a PSA density of approximately 0.23.

The first result is much more likely to reflect benign prostate enlargement. The second deserves substantially greater attention.

PSA density is particularly valuable when MRI is negative or equivocal. Current European guidance recognises PSA density as an important predictor of clinically significant cancer and uses it alongside the MRI score when determining whether biopsy can safely be omitted.

Cut-offs such as 0.10, 0.15 or 0.20 ng/mL/cc may be used, but the appropriate threshold depends on the MRI appearance, family history, previous biopsy history and the clinical setting.

PSA velocity and PSA doubling time

PSA velocity describes how quickly PSA is increasing.

A sustained rise across several properly performed tests is more informative than a single change between two readings. Day-to-day biological and laboratory variation can be considerable, so apparent “velocity” based on two closely spaced tests may be misleading.

PSA kinetics are particularly useful:

• during active surveillance;
• after prostate cancer treatment;
• when reviewing several years of results; and
• when deciding how closely a man should be monitored.

PSA velocity should not usually be used as the sole reason for biopsy.

Baseline PSA and risk-adapted testing

A baseline PSA in a man’s forties or early fifties may help estimate his longer-term risk.

A man whose PSA is well below the median for his age may be able to wait longer before retesting. A result above the expected range for his age may justify closer follow-up even when it remains below a formal referral threshold.

European guidance supports risk-adapted intervals based on the initial PSA rather than testing every man at the same frequency.

Why MRI before biopsy changed the PSA pathway

The most important development in prostate cancer diagnosis over the past decade has been the introduction of MRI before biopsy.

Previously, biopsy needles were placed systematically throughout the prostate without knowing whether a suspicious lesion was present or where it lay. This could:

• miss an important cancer;
• find a small insignificant cancer;
• subject men without significant disease to an invasive procedure; and
• expose patients to infection from the transrectal approach.

The PROMIS study demonstrated the value of multiparametric MRI as a triage test before biopsy. In that study, approximately 27% of participants had a negative MRI, although a negative scan did not exclude every clinically significant cancer.

MRI allows the diagnostic team to assess:

• whether a suspicious lesion is visible;
• how suspicious it appears;
• where it is located;
• whether there are signs of spread outside the prostate; and
• where to take targeted biopsy samples.

In UK practice, scans may be graded using a five-point Likert or PI-RADS scale.

A low-scoring MRI combined with a low PSA density and reassuring clinical features may allow biopsy to be avoided. A suspicious lesion or a high PSA density makes biopsy more likely to be appropriate.

MRI is not perfect. Some clinically significant cancers are not clearly visible, and benign inflammation or enlargement can produce suspicious appearances. The scan must therefore be interpreted alongside PSA density and individual risk.

Is transperineal prostate biopsy safer?

When biopsy is required, the transperineal approach passes the needles through the cleaned skin between the scrotum and anus rather than through the rectum.

This substantially reduces the risk of serious infection compared with traditional transrectal biopsy. It can usually be performed under local anaesthetic.

It does not make biopsy risk-free. Temporary blood in the urine or semen, discomfort and difficulty passing urine can still occur.

When MRI identifies a lesion, targeted samples are taken from that area. Additional systematic or perilesional samples may also be needed, particularly in men having their first biopsy. Current European guidance recommends targeted biopsy with perilesional sampling for appropriate MRI-positive lesions, rather than assuming target-only biopsy is adequate for every patient.

Blood test alternatives to PSA

Most alternative prostate cancer blood tests are designed to help decide whether a man with a raised PSA genuinely needs MRI or biopsy.

They should not be confused with diagnostic tests that prove cancer is present.

Prostate Health Index

The Prostate Health Index, usually abbreviated to PHI, combines:

• total PSA;
• free PSA; and
• a PSA precursor called p2PSA.

The values are combined into a single score estimating the likelihood of prostate cancer, particularly clinically significant disease.

PHI is better at risk discrimination than total PSA alone in appropriately selected men and can help reduce unnecessary MRI scans or biopsies. Both PHI and the 4Kscore are recognised in European guidance as biomarker panels intended to reduce unnecessary biopsy after PSA testing.

PHI is one of the more useful secondary blood tests when PSA remains moderately raised, but the decision about further investigation is genuinely uncertain.

4Kscore

The 4Kscore measures four kallikrein proteins:

• total PSA;
• free PSA;
• intact PSA; and
• human kallikrein 2.

The result is combined with clinical information such as age, examination findings and previous biopsy history to estimate the probability of higher-grade prostate cancer.

Like PHI, it is principally a biopsy risk-assessment test, not a population screening replacement for PSA.

Its availability in the UK is more limited than in the United States, and any result should be interpreted within a specialist diagnostic pathway.

Stockholm3

Stockholm3 is one of the most sophisticated blood-based prostate cancer risk tests currently available.

It combines:

• PSA and other protein biomarkers;
• more than 100 inherited genetic variants;
• age;
• family history;
• previous biopsy information; and
• other clinical factors.

The result estimates the risk of clinically significant prostate cancer rather than relying on PSA concentration alone.

In a 2026 population-based analysis of 12,670 men, Stockholm3 at the study’s specified threshold showed sensitivity of approximately 90% for Grade Group 2 or higher cancer, compared with approximately 74% for PSA at a threshold of 3 ng/mL. Specificity was similar.

This is an important finding because it suggests that a multivariable blood test may detect more significant cancers while maintaining a similar rate of positive tests.

There are, however, important qualifications:

• these results apply to the thresholds and population studied;
• much of the screening evidence has come from Scandinavia;
• Stockholm3 is not part of routine NHS screening;
• cost and laboratory availability remain considerations; and
• evidence that a test improves detection does not automatically prove that it reduces prostate cancer mortality.

Stockholm3 is therefore best regarded as one of the most credible candidates for a future risk-adapted pathway—not as an established replacement for PSA throughout the UK.

IsoPSA

IsoPSA examines structural changes in PSA molecules rather than simply measuring how much PSA is present.

Cancer can change PSA’s molecular form. IsoPSA attempts to identify those altered structures and estimate the risk of higher-grade cancer.

Prospective multicentre studies have shown improved discrimination compared with conventional PSA measurements, although availability in the UK remains limited.

Proclarix

Proclarix combines total and free PSA with two additional proteins:

• thrombospondin-1; and
• cathepsin D.

It has mainly been studied in men with moderately raised PSA and may be useful in selected patients, including some with equivocal MRI findings.

Its evidence base and routine availability are less extensive than those of PHI, 4Kscore or Stockholm3.

EpiSwitch PSE

EpiSwitch PSE combines PSA with an epigenetic chromosome-conformation signature measured in blood cells.

Published studies and real-world clinical utility data are encouraging, but the independent evidence base remains less mature than for the most established biomarker tests.

It should therefore be interpreted cautiously and should not be used in isolation to overrule concerning MRI, PSA density or clinical findings.

Urine tests for prostate cancer

Urine can contain prostate cells, RNA and other biological material shed into the urethra.

Several urine tests aim to identify molecular patterns associated with clinically significant prostate cancer.

MyProstateScore 2.0

MyProstateScore 2.0, or MPS2, is an 18-gene urine test designed to identify higher-grade prostate cancer.

In its 2024 validation study, MPS2 achieved high negative predictive values for Grade Group 2 or higher and Grade Group 3 or higher cancer. Depending on the population and model used, it could potentially have avoided approximately 35% to 51% of unnecessary biopsies while preserving high sensitivity.

This makes it one of the most promising contemporary urine biomarkers.

However:

• the studies were conducted in referred diagnostic populations;
• performance depends on the threshold selected;
• it is not yet a proven population screening test; and
• UK access remains limited.

It may become particularly useful because newer versions can analyse first-catch urine without requiring a preceding rectal examination.

ExoDx Prostate Intelliscore

ExoDx analyses RNA contained within urinary exosomes—small particles released by cells.

It does not require a rectal examination before urine collection and has been validated in men with moderately raised PSA who are considering an initial biopsy.

The test is used mainly in the United States and is not routinely available through UK pathways. Prospective studies have supported its role in predicting Grade Group 2 or higher cancer.

SelectMDx

SelectMDx assesses the expression of the HOXC6 and DLX1 genes in urine and combines the result with clinical risk factors.

It may help identify men at lower risk of significant cancer, but its added value depends on how it is combined with MRI and established clinical measures.

PCA3

PCA3 was one of the first widely discussed urine biomarkers for prostate cancer.

Its principal limitation is that it is better at predicting whether any prostate cancer is present than at reliably distinguishing harmless disease from clinically significant cancer.

That distinction is now the central aim of modern diagnosis. PCA3 has therefore been largely overtaken by MRI and newer multigene urine tests.

Genetic tests and inherited prostate cancer risk

Genetic testing can mean two different things:

1. looking for a single inherited variant that substantially increases risk; or
2. combining many common genetic variants into a polygenic risk score.

These tests do not show whether a man currently has prostate cancer. They estimate inherited susceptibility.

Germline genetic testing

A germline variant is an inherited change present in every cell of the body.

BRCA2 is particularly important in prostate cancer. Men with a pathogenic BRCA2 variant have a higher risk of developing prostate cancer and are more likely to develop aggressive disease.

Other relevant genes can include:

• BRCA1;
• HOXB13;
• ATM;
• CHEK2; and
• the DNA mismatch-repair genes associated with Lynch syndrome.

Germline testing may be appropriate where there is:

• prostate cancer diagnosed unusually young;
• several relatives with prostate cancer;
• relatives with breast, ovarian or pancreatic cancer;
• a known cancer-predisposition variant in the family; or
• particular tumour features in a man already diagnosed with cancer.

Genetic counselling is important because the result may affect not only the patient but also his relatives.

Polygenic risk scores and saliva testing

A polygenic risk score combines the small effects of many common genetic variants.

Unlike PSA, which can change over time, inherited genetic risk is fixed at conception. It therefore only needs to be measured once.

The UK BARCODE1 study used a saliva sample to calculate a score based on 130 prostate cancer-associated variants. Men in the highest-risk decile were offered MRI and biopsy. The study demonstrated that genetic risk assessment can identify cancers—including significant cancers—in men who may not have been selected by PSA alone.

This is promising, but it requires careful interpretation.

BARCODE1 was not a randomised head-to-head screening trial comparing polygenic testing with PSA or MRI across the whole population. It has not yet shown that polygenic screening reduces prostate cancer deaths or produces more overall benefit than harm. Subsequent academic discussion has highlighted these limitations.

Polygenic risk scores may eventually help determine who should enter a screening programme and how frequently they should be tested. They are not currently a diagnostic replacement for PSA, MRI or biopsy.

ConfirmMDx

ConfirmMDx is a tissue-based test for men who have already undergone a prostate biopsy that did not show cancer.

It examines DNA methylation patterns in apparently benign biopsy tissue. The principle is that tissue near a tumour may carry epigenetic changes even when the biopsy needle has not directly sampled the cancer.

Its role has become narrower as MRI and targeted biopsy have improved, but it may still be useful in selected men with persistent suspicion after a negative biopsy.

Imaging alternatives and newer diagnostic technology

Biparametric MRI

A full multiparametric MRI normally includes:

• T2-weighted imaging;
• diffusion-weighted imaging; and
• contrast-enhanced sequences.

Biparametric MRI generally omits the intravenous contrast component.

This can make scanning:

• faster;
• less expensive;
• easier to scale;
• suitable for men who should avoid gadolinium contrast.

Research suggests that well-performed biparametric MRI can achieve broadly comparable diagnostic performance in appropriate settings. Rapid MRI is therefore being investigated as a possible component of future screening.

Micro-ultrasound

Micro-ultrasound uses a high-frequency transducer to produce images of the prostate at much higher resolution than conventional ultrasound.

Unlike MRI, it can be used during the biopsy itself, allowing suspicious areas to be identified and sampled in real time.

The international OPTIMUM randomised trial included 678 biopsy-naïve men and found micro-ultrasound-guided biopsy to be non-inferior to MRI-fusion-guided biopsy for detecting Grade Group 2 or higher prostate cancer.

This is encouraging, particularly in healthcare systems with limited MRI access.

It does not yet prove that micro-ultrasound should replace every part of an MRI-led pathway. Operator training, quality assurance and further real-world evidence will be important.

PSMA PET-CT

PSMA PET-CT is an exceptionally valuable scan in selected men who have already been diagnosed with prostate cancer.

It is increasingly used to:

• stage higher-risk disease;
• detect lymph-node or distant spread;
• investigate recurrence after treatment; and
• find disease at relatively low PSA levels after surgery or radiotherapy.

It is not currently a routine screening test or the standard first investigation for an undiagnosed raised PSA. Cost, radiation exposure, availability and the potential for incidental findings make it unsuitable for general screening at present.

What is happening with prostate cancer screening in the UK?

The position changed significantly in 2026.

The UK National Screening Committee:

• did not recommend population screening for all men;
• recommended PSA testing every two years for men aged 45–61 who have both a pathogenic BRCA2 variant and a relevant family history of breast, ovarian, pancreatic or prostate cancer;
• did not recommend targeted screening for other risk groups at present; and
• committed to considering emerging evidence from studies including TRANSFORM.

Ministers in England accepted the recommendation, and the targeted programme is expected to begin rolling out in 2027. Health is devolved, so Scotland, Wales and Northern Ireland make implementation decisions separately.

The programme is narrow. It does not currently include:

• all men over 50;
• Black men as a group;
• every man with a family history;
• BRCA1 carriers without another qualifying indication.

This does not mean that those men are at average risk. It means that the UK National Screening Committee judged that the available screening evidence was insufficient to prove that routinely inviting those groups would currently produce more benefit than harm.

What is the TRANSFORM trial?

TRANSFORM is a major UK research programme designed to determine how to make prostate cancer screening safer and more accurate.

Following an additional government investment of up to £18 million in June 2026, total investment in TRANSFORM increased to approximately £60 million.

The trial is investigating screening approaches involving combinations of:

• PSA blood testing;
• rapid MRI;
• genetic or polygenic risk assessment; and
• risk-adapted diagnostic pathways.

The trial is not itself a national screening programme.

Its first stage includes targeted recruitment of Black men. If stage-one outcomes are successful, the expanded second stage is intended to invite all eligible Black men aged 45–74 who meet the trial criteria. Participation is by invitation, not self-referral.

TRANSFORM matters not simply because it finds another test. It compares complete screening strategies and determines which combination finds dangerous cancers early while avoiding unnecessary diagnosis and treatment.

How I approach a raised PSA in clinical practice

Guidelines describe populations. A clinic contains an individual man.

My approach is therefore based on the whole clinical picture rather than a single number.

1. Establish the baseline risk

I consider:

• age;
• ethnicity;
• family history;
• previous PSA results;
• urinary symptoms;
• medication;
• general health; and
• whether the man would benefit from finding an early cancer.

2. Confirm a moderately raised result

When clinically safe, I exclude infection and repeat a moderately elevated PSA under standardised conditions before escalating the investigation.

A single unexpected result should not automatically lead to biopsy.

3. Look at the pattern over time

A stable PSA associated with a large benign prostate may mean something very different from a steady rise in a younger man with a small gland.

4. Use additional biomarkers selectively

PHI, Stockholm3, or another secondary test may help when the decision remains uncertain, and the result would genuinely alter management.

Ordering a sophisticated biomarker adds little value if clinical findings already make MRI or biopsy clearly necessary.

5. Perform MRI before biopsy in suspected localised disease

For most men being investigated for possible organ-confined prostate cancer, MRI should ordinarily be performed before biopsy.

MRI identifies suspicious areas, estimates prostate volume and provides the information required to calculate PSA density.

6. Combine the MRI score with PSA density

An equivocal MRI lesion with a low PSA density may be managed very differently from the same lesion in a man with a high PSA density, a strong family history and a rising PSA.

7. Biopsy transperineally when biopsy is indicated

The biopsy should target suspicious MRI lesions and include additional sampling where clinically appropriate.

8. Separate diagnosis from treatment

Finding prostate cancer does not mean that radical treatment is inevitable.

Many men with low-risk prostate cancer are best managed with active surveillance. The aim is to identify cancers that could become harmful while avoiding unnecessary treatment of cancers that are unlikely to affect length or quality of life.

Which prostate cancer test is best?

There is no single “best” test for every man.

The most useful test depends on the question being asked.

To begin assessing risk

PSA remains the most accessible and established first-line blood test.

To confirm that a raised result is genuine

A properly timed repeat PSA is often the most useful next step.

To adjust for prostate enlargement

PSA density is extremely valuable.

To refine an uncertain biopsy decision

PHI, 4Kscore, Stockholm3 or selected urine tests may help.

To locate suspicious disease

Prostate MRI is currently the central imaging test.

To identify inherited susceptibility

Germline testing or a polygenic risk score may be appropriate.

To diagnose cancer definitively

A biopsy is still required in most cases where tissue confirmation will affect management.

Frequently asked questions

Key points

• PSA is prostate-specific but not prostate cancer-specific.
• A raised PSA does not automatically mean cancer.
• A relatively low PSA cannot exclude every significant cancer.
• A moderately raised PSA should often be repeated under standardised conditions.
• PSA density is one of the most useful ways to interpret PSA in the context of prostate size.
• MRI before biopsy has transformed the diagnostic pathway.
• PHI, 4Kscore and Stockholm3 are among the better-validated secondary blood tests.
• MPS2 is one of the most promising newer urine tests.
• Genetic testing identifies inherited susceptibility; it does not diagnose an existing cancer.
• Transperineal biopsy has substantially reduced the risk of serious infection.
• The UK has not introduced population screening for all men.
• England is expected to introduce targeted screening from 2027 for a narrowly defined group of men with a pathogenic BRCA2 variant and relevant family history.
• The best diagnostic approach combines PSA with personal risk, prostate volume, MRI and selective additional testing.

When should I see a urologist?

Specialist assessment may be helpful if:

• your PSA remains raised when repeated;
• your PSA is rising over time;
• your result appears high for your age;
• you have a strong family history of prostate, breast, ovarian or pancreatic cancer;
• you are known to carry a BRCA2 or another relevant genetic variant;
• you have an abnormal prostate examination;
• your MRI is abnormal or unclear;
• you have been advised to consider prostate biopsy; or
• you remain concerned despite an apparently reassuring initial assessment.

A specialist consultation should not focus only on whether a biopsy can find cancer. It should consider the probability of finding clinically significant disease, the possible benefits of diagnosis and the potential consequences of further investigation.

---

About Mr Neil Haldar

Mr Neil Haldar is a Consultant Urological Surgeon with extensive experience in prostate cancer diagnosis, robotic and minimally invasive uro-oncology, and the assessment of men with raised PSA results.

He provides specialist urological consultations across Buckinghamshire, Berkshire, Hertfordshire, Oxfordshire and London.

---

Medical disclaimer

This article provides general information and does not replace individual medical advice. PSA results and prostate cancer risk should be interpreted in the context of age, symptoms, medication, prostate size, family history, ethnicity, previous results and general health.

Seek medical advice from your GP or a suitably qualified urologist if you are concerned about your PSA result or prostate cancer risk.

Sources and further reading

• UK National Screening Committee: prostate cancer screening recommendation, 2026.
• Department of Health and Social Care: targeted screening and TRANSFORM expansion, June 2026.
• NICE NG12: age-specific PSA referral thresholds.
• European Association of Urology: prostate cancer diagnostic evaluation guidance.
• PROMIS study of MRI before prostate biopsy.
• Stockholm3-MRI two-year population follow-up.
• MPS2 18-gene urine test validation.
• BARCODE1 polygenic risk-score study.
• OPTIMUM micro-ultrasound randomised trial.
• Prostate Cancer UK: TRANSFORM programme.